SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WeirdPro Randy who wrote (355)5/17/1997 6:51:00 PM
From: Miljenko Zuanic   of 998
 
Randy,

I am completely on your side. If FDA wont to stand as independent government institution with power to role in their field (approval or rejection the NDA)-protection of the patients interest should be prime objective, than there should not be any ambiguity regards the Myotrophin. Also, any political influents should be eliminated. It was surprise that professional institutions account "political factors" in their assessment for FDA rule on Myotrophin, when is obviously that drug is scam.

To reply on NeuroInvestment post regards the correlation of the Sibutramine (Knoll) for obesity and Myotrophin. Sibutramine show better efficiency than Redux and Advisory vote (one vote difference I think) against drug because of the possible side effects. There was no big deal for FDA to overrule Advisory decision (which was also , IMO, political) and approve Sibutramine. Myotrophin is opposite situation: no serious side effects, but no efficiency.

This is real task for FDA and they have to show where they stand!

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News